Dr. Brian Wood introduces long acting, injectable Cabotegravir-Rilpivirine, the first approved intramuscular ART. He reviews patient eligibility, the two dosing options (every 1-month or every 2 months), and recommendations on how to manage a planned missed injection. He also discusses clinical trial data and a recent update to HHS guidelines about the timing of a genotype resistance assay after stoppage of this ART.

0:00 Intro
0:18 Oral and Injectable Preparations
0:50 CAB-RPV Extended Release Injectable Suspension Indications
2:44 Schedule for Every 1-Month Injectable
5:14 Management of Missed Injections 1-Month Dosing
6:02 Restarting Injection Doses 1-Month Dosing
6:59 Schedule for Every 2 Month Injectable
8:02 Management of Missed Injections 2-Month Dosing
8:37 Restarting Injection Doses 2-Month Dosing
10:04 Switching Dosing to 1 or 2-Month
11:05 ATLAS Study
14:45 ATLAS-2M
17:19 Considerations if Adherence Challenges or Virologic Failure
19:31 Summary